SCHEMBL1047728

SCHEMBL1047728

CC(C)S(=O)(=O)c1ccccc1Nc1cc2cc[nH]c(=O)c2c(Nc2ccc(N3CCOCC3)cc2)n1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 10/20 0.69
TTK P33981 3/20 0.52
PTK2 Q05397 4/20 0.46
ALK Q9UM73 3/20 0.46
GAK O14976 1/20 0.46
INSR P06213 1/20 0.46
IGF1R P08069 1/20 0.46
INSRR P14616 1/20 0.46
MAPK1 P28482 1/20 0.46
LTK P29376 1/20 0.46
CLK1 P49759 1/20 0.46
TNK2 Q07912 1/20 0.46
TNK1 Q13470 1/20 0.46
PTK2B Q14289 1/20 0.46
MAP4K1 Q92918 1/20 0.43
JAK2 O60674 1/20 0.41
SYK P43405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047800 0.92 ZAP70 (0.67) ZAP70TTKPTK2ALKGAK
SCHEMBL1049000 0.92 ZAP70 (0.73) ZAP70TTKPTK2IGF1RMAP4K1
SCHEMBL1049400 0.89 ZAP70 (0.70) ZAP70TTKIGF1RMAP4K1JAK2
SCHEMBL1047387 0.89 ZAP70 (0.77) ZAP70TTKMAP4K1JAK2SYK
SCHEMBL1044892 0.89 ZAP70 (0.69) ZAP70TTKIGF1RMAP4K1JAK2
SCHEMBL1047730 0.87 ZAP70 (0.67) ZAP70TTKIGF1RMAP4K1JAK2
SCHEMBL1045837 0.87 ZAP70 (0.67) ZAP70TTKIGF1RMAP4K1JAK2
SCHEMBL1049428 0.82 ZAP70 (0.66) ZAP70PTK2INSRIGF1RPTK2B
SCHEMBL1046388 0.82 ZAP70 (1.00) ZAP70JAK2SYK
SCHEMBL12928944 0.81 ZAP70 (0.64) ZAP70IGF1RJAK2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885TTK 537/4885PTK2 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.